Lecia Sequist studied chemistry at Cornell University, received her MD from Harvard Medical School and trained in internal medicine at the Brigham and Women’s Hospital and in hematology/oncology at the Dana-Farber Cancer Institute, where she also received an MPH from the Harvard School of Public Health. She joined the faculty at the Massachusetts General Hospital Cancer Center in 2005 and has an active clinical and translational research career, as well as a busy practice caring for patients with lung cancer. She is currently the Landry Family Professor of Medicine at Harvard Medical School and the Program Director of the Cancer Early Detection and Diagnostics Clinic at Mass General Cancer Center. She has held grants from the NIH, the DOD, and many private foundations. Dr. Sequist’s research focuses on studying targeted therapeutics for lung cancer and bringing new non-invasive tests like circulating tumor cells and circulating tumor DNA to treat and detect lung cancer. Dr. Sequist is one of the 2022 DF/HCC Incubator Award winners for her work on the ‘Assessment of novel technologies for early detection of cancer in individuals with germline cancer predisposition’ team.
